Glaxosmithkline Intellectual Property Development Limited

Fimbrion Therapeutics, Inc.

Glaxosmithkline LLC

Smithkline Beecham Corporation

Novartis Vaccines & Diagnostics, Gmbh

Stiefel Laboratories, Inc.

Ardent Pharmaceuticals, Inc.

Michael Joseph Bishop

James Walter Janetka

Jason Daniel Speake

Katherine Louisa Widdowson

David Lee Musso

Eugene L Stewart

Rodolfo Cadilla

David John Cowan

Andrew Lamont Larkin

Paul Kenneth Spearing

Cunyu Zhang

Gary Martin Green

Laurel Kathryn Mcgrane

Laurel Kathryn McGrane

Daniel T Chu

Aaron Matthew Smith

Kwen-Jen Chang

Stephen Andrew Thomson

Rustum S Boyce

David Harold Drewry

Natalia Aurrecoechea

Frank Navas, Iii

Robert W McNutt, Jr

Hugh O Pettit

Stephen J Hodson

Christopher R Conlee

Kien S Du

Brian D Thompson

Vincent J Colandrea

Xue Ge

Hansen Wong

Wendy Huang Chern

Hans Hofland

Judith De Armas Kuntz

Kevin K Barvian

Xin Frank Cai

William R Swain

Alan Colborn

Brian A Chauder

Eric Cleveland Bigham

Deanna Trojan Garrison

Yuehu Li

Iulia Strambeanu

Disclosed herein are new O-biphenyl- and O-phenylheteroarylmannoside compounds and compositions and their application as pharmaceuticals for use in the treatment of human disease. Methods of inhibition of FimH activity in human subjects are also provided for the treatment of diseases such as urinary tract infection.

Substituted biphenyl or phenylheteroaryl-mannosides as antagonists of FimH

Disclosed herein are new C-mannoside compounds and compositions and their application as pharmaceuticals for the treatment of human disease. Methods of inhibition of FimH activity in human subjects are also provided for the treatment diseases such as urinary tract infection.

Compounds

Disclosed herein are C-mannoside compounds, compositions thereof and their application as pharmaceuticals for the treatment of human disease. Methods of inhibition of FimH activity in a human subject are also provided for the treatment of diseases such as bacterial infection, Crohn's disease (CD) and Inflammatory Bowel Disease (IBD).

C-mannoside compounds useful for the treatment of urinary tract infections

Disclosed herein are new C-mannoside compounds and compositions and their application as pharmaceuticals for the treatment of human disease. Methods of inhibition of FimH activity in a human subject are also provided for the treatment diseases such as urinary tract infection.

The presently described subject matter relates to new derivatives of tazarotene that also exhibit retinoid activity, pharmaceutical compositions comprising the derivatives, method of treating skin disorders with the pharmaceutical compositions, and process of making the derivatives.

Tazarotene derivatives

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction

Compounds as antagonists or inverse agonists at opioid receptors

A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the structure IA, IB, and IC where the values of the variables are defined herein. 

Substituted quinazolinone compounds

A method of reducing, treating or preventing drug-mediated respiratory depression, muscle rigidity, or nausea/vomiting in an animal, incident to the administration to said animal of a mixed delta/mu opioid agonist or a respiratory depression-mediating drug, comprising administering to the animal receiving said drug an effective amount of a delta receptor agonist compound. Preferred examples of such delta receptor agonist compound include diarylmethyl piperazine compounds and diarylmethyl piperidine compounds, and pharmaceutical compositions thereof, having utility in medical therapy for reducing respiratory depression associated with certain analgesics, such as mu opiates.

Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds

Compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof are disclosed. Such compounds are useful in the treatment of Alpha-1A mediated diseases or conditions such as urinary incontinence.

Imidazoline derivatives as alpha-1A adrenoceptor ligands

Growing community of inventors

Chapel Hill, NC, United States of America

Michael Joseph Bishop